Moving Kidney Organoids from the Lab Bench Toward Mass Production: US–Taiwan Team Receives Up to $4.3 Million in ARPA-H Support

Kidney organoids can simulate some organ structures and functions in a culture dish, but they cannot necessarily be manufactured consistently and at scale. This gap between being able to “make them” and being able to “make enough of them consistently in every batch” is a core obstacle to bringing organoids into regenerative medicine. The US Advanced Research Projects Agency for Health (ARPA-H) is now providing up to $4.3 million to support AcroCyte Therapeutics in establishing a scalable production process for human kidney organoids.

ARPA-H information shows that the project, named RACE, is led by AcroCyte as the primary award recipient and headed by Ying Chih Chang. It launched on March 19, 2026. The company announced the award on July 23, stating that the project will combine clinical and R&D resources in the United States and Taiwan and advance translational development with the University of Chicago Medical Center and National Taiwan University Hospital.

The project’s technical starting point is AcroCyte’s R3CE cell expansion platform. The team aims to obtain still-functional kidney progenitor cells from patients themselves, screen them, then expand them at scale and produce kidney organoid modules. The rationale for using autologous cells is to allow the product to retain each patient’s individual biological characteristics and potentially reduce the risk of immune rejection caused by allogeneic cells. However, differences in cell quality between individuals will also make process standardization more difficult.

The milestones listed by ARPA-H include obtaining viable kidney tissue, establishing mass-production capacity for kidney organoids, and evaluating organoid therapy in animal models. The target disease is chronic kidney disease, while the long-term directions include organoid therapies and bioartificial kidneys. This indicates that the project remains at the process-establishment and preclinical validation stage, with no human efficacy or safety data yet available.

For organoids to become usable therapeutic products, cell quantity is not the only challenge. Whether different batches can maintain similar cellular composition, maturity, and kidney function, and whether they can survive after implantation, form appropriate blood vessels, and work in coordination with host tissue all require reproducible evidence. Autologous manufacturing also involves sampling conditions, waiting times, costs, and quality-release standards. These issues will determine whether the technology can transition from a research-scale process to a clinically viable supply model.

The practical significance of this funding, therefore, is not that it proves kidneys can already be regenerated, but that it brings the often-overlooked manufacturing challenges of organoid therapy into a milestone-based development pathway. Only if the team first demonstrates that kidney progenitor cells can be expanded consistently and organoids can be mass-produced with consistent quality, followed by evidence of functional and safety signals in animal models, could it lay the groundwork for subsequent regulatory discussions and early human studies.